Ask AI
ProCE Banner Activity

Optimizing First-line Maintenance for HER2+ MBC: Equipping the Multidisciplinary Team With the Latest Evidence and Guidance on Novel Regimens 

Slideset

Download these slides to explore the latest evidence and practical guidance on first-line maintenance therapy for HER2-positive MBC, including how to select and sequence emerging regimens based on patient and disease factors. Gain multidisciplinary strategies for monitoring and managing key toxicities and supportive care needs to optimize outcomes in community practice.

Released: March 19, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from Pfizer Inc.

Pfizer Inc.

Target Audience

This activity is intended for community medical oncologists, nurse practitioners, physician associates, nurses, pharmacists, and other healthcare professionals who care for patients with breast cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Educate patients on the clinical role and risk–benefit profile of first-line maintenance therapy for HER2-positive MBC

  • Evaluate the potential of novel combinations to optimize patient outcomes in the first-line maintenance setting for HER2-positive MBC using the latest evidence

  • Recommend the optimal first-line maintenance therapy for each eligible patient with HER2-positive MBC based on expert recommendations, evidence, HR status, and patient goals

  • Implement evidence-based multidisciplinary strategies to manage toxicities related to novel first-line maintenance therapies for HER2-positive MBC